about
Relative survival of patients with non-malignant central nervous system tumours: a descriptive study by the Austrian Brain Tumour RegistryWhat is the Surgical Benefit of Utilizing 5-Aminolevulinic Acid for Fluorescence-Guided Surgery of Malignant Gliomas?Outcome evaluation in glioblastoma patients older than 65 years: Importance of individual assessment of treatment tolerance.5-Aminolevulinic acid is a promising marker for detection of anaplastic foci in diffusely infiltrating gliomas with nonsignificant contrast enhancement.Alleviation of brain edema and restoration of functional independence by bevacizumab in brain-metastatic breast cancer: a case report.Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases.Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches.Arterial spin-labeling assessment of normalized vascular intratumoral signal intensity as a predictor of histologic grade of astrocytic neoplasms.5-Aminolevulinic acid induced fluorescence is a powerful intraoperative marker for precise histopathological grading of gliomas with non-significant contrast-enhancementBrain tumours at 7T MRI compared to 3T--contrast effect after half and full standard contrast agent dose: initial results.Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors.Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.Atypical teratoid rhabdoid tumor: improved long-term survival with an intensive multimodal therapy and delayed radiotherapy. The Medical University of Vienna Experience 1992-2012.Local image variance of 7 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational statusαvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer.Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review.Correlation of immune phenotype with IDH mutation in diffuse glioma.Analysis of the surgical benefits of 5-ALA-induced fluorescence in intracranial meningiomas: experience in 204 meningiomas.Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).A novel miniature robotic guidance device for stereotactic neurosurgical interventions: preliminary experience with the iSYS1 robot.Expression profiling of angiogenesis-related genes in brain metastases of lung cancer and melanoma.Introduction of a standardized multimodality image protocol for navigation-guided surgery of suspected low-grade gliomas.Clinical Neuropathology practice news 1-2014: pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma.Correlation of microvascular fractal dimension with positron emission tomography [(11)C]-methionine uptake in glioblastoma multiforme: preliminary findings.Clinical neuropathology practice guide 1-2013: molecular subtyping of glioblastoma: ready for clinical use?The value of intraoperative motor evoked potential monitoring during surgical intervention for thoracic idiopathic spinal cord herniation.High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer.A management algorithm for cerebrospinal fluid leak associated with anterior skull base fractures: detailed clinical and radiological follow-up.Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases.Intra-operative visualization of brain tumors with 5-aminolevulinic acid-induced fluorescence.O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL).Amplification and overexpression of CMET is a common event in brain metastases of non-small cell lung cancer.Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study.ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer.The course of quality of life and neurocognition in newly diagnosed patients with glioblastoma.Visual and semiquantitative 11C-methionine PET: An independent prognostic factor for survival of newly diagnosed and treatment naive gliomas.Bioimaging and surgery of brain tumors.Analysis of 5-aminolevulinic acid-induced fluorescence in 55 different spinal tumors.Comparison of microRNA expression levels between initial and recurrent glioblastoma specimens.
P50
Q30420487-0E1FF602-908A-4F19-9B9B-C4EB96BB546FQ30989894-7D524CF4-FDCB-4E0F-BB7E-2D7ED9941A2AQ33417332-C9D76D64-BCD6-411A-9C58-AF640BAFD6DEQ33527053-DFC48561-3674-40B5-8A4E-B990C8F7F453Q33684824-B60A095B-D1AE-428D-BC84-AD4F2A5D1BF7Q33854543-B3AED523-62D9-43C9-9D51-876581B5D2CEQ34249977-CB6E14BE-920E-489B-9F7E-297A68F37026Q34941302-9525A8D0-610F-49B1-BD4C-61ED8B474AB9Q35034931-29B47972-9904-486B-8EBA-1BF05B4291FEQ35187924-267208A9-1CC5-4F7B-AFAF-9F752F67C79EQ36385329-8773A7F3-044D-443D-8171-F78F3F118ED7Q36597510-B60A446C-2548-4D2B-A900-11BBDFAD9E53Q37595251-03813614-4C71-47A5-97EF-117DC949C089Q37677994-C5F1B3D6-33F4-4506-B485-504D86814F17Q38242534-57FA2901-C794-42B3-85E9-54DA45DE27CFQ38302642-4C1EB304-2504-4FAF-AF9C-6388458D47D7Q38771020-C0D75E5A-8A17-445D-811E-802536C3297DQ38890141-B8422DA3-3AFD-40DA-B6F3-2E090C482253Q39583147-AB641BA3-2CD0-466C-98A9-27F2DC056B31Q39830480-178520CB-70AD-49DD-BDCD-89476381B219Q40638741-5499815B-07F2-4DD0-AF69-9EC022017CC9Q41635052-271FFB06-A1C2-40EE-99FC-9A1C1EC3BB2AQ41870675-BE838A63-C56E-4D94-BE00-58A8A8D0E23AQ43098306-3114B0BA-1433-4AA4-8B85-1E398C0A6547Q43149195-80461982-CF2A-4CF1-BDF2-1CE8F18EC0DAQ44235101-69ECE09D-6FDA-40D6-BDE3-2E17E7B45FDDQ44362363-42BFF0C3-F768-4A2E-8FD1-30267B2667B7Q45016726-0424D6EC-6CCC-4E70-A269-8CAC08FB4CFFQ45905781-EF903F05-2E86-45AE-B3B4-88BBB89DC7E0Q45956227-36E7BC38-DA54-4BE9-A698-B3F27EEDF6EDQ46154959-ADFA38BE-9276-4533-85DF-D34058C86C92Q46383199-21FBC610-BD11-42DD-86F5-3D024D54079FQ46562452-9207C0B8-65DD-4935-843B-B5AC4A8AFEF9Q46610505-088C2B62-28B7-4BEE-B36A-41B4002EE531Q46649061-43E43D20-9C0F-4D85-BAE3-42BB9C217336Q47299113-88EDC922-E73B-467B-86EF-4EB0A20436EFQ47583631-6C62524C-13BA-4AEF-9C82-4DC246BCDDE1Q47846223-7CBE6F25-CA9E-44FA-A712-006BC64B7966Q47917537-9A5DAB10-3535-4E1D-BA1C-41366592510FQ48158056-8300C41F-19D0-44F6-ABFC-1913EA2B3FE5
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Georg Widhalm
@ast
Georg Widhalm
@en
Georg Widhalm
@es
Georg Widhalm
@nl
type
label
Georg Widhalm
@ast
Georg Widhalm
@en
Georg Widhalm
@es
Georg Widhalm
@nl
prefLabel
Georg Widhalm
@ast
Georg Widhalm
@en
Georg Widhalm
@es
Georg Widhalm
@nl
P106
P21
P31
P496
0000-0001-6014-0273